

HCV Directly Acting Antivirals & RBV

Charts revised July 2018. Full information available at www.hep-druginteractions.org

Page 1 of 5

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Caution Note: If a drug is not listed it cannot automatically be assumed it is safe to co-administer. DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; GLP/PIB, Gilecparevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Omibitasvir/Parataprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin. Cells have been left blank for the unassessed interactions with RBV.

Key to symbols

- These drugs should not be coadministered
- Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
- ▲ Potential interaction likely to be of weak intensity.
Additional action/monitoring or dosage adjustment is unlikely to be required
- ◆ No clinically significant interaction expected

Notes

- Notes**

 - Further information is available at www.hep-druginteractions.org
 - Predicted interactions are based on known metabolic pathways. Interaction studies performed with boceprevir and telaprevir have shown some inconsistencies which suggest unknown mechanisms may contribute to drug-drug interactions and therefore predictions may not always reflect the clinical situation.
 - Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
 - Where advice differs between countries, the charts reflect the more cautious option

© Liverpool Drug Interactions Group,
University of Liverpool

University of Liverpool
Pharmacology Research Labs, 1st Floor Block H,
70 Pembroke Place, LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or

HCV Directly Acting Antivirals & RBV

Charts revised July 2018. Full information available at www.hep-druginteractions.org

Page 2 of 5

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

lease note that if a drug is not listed it cannot automatically be assumed it has no interactions with RBV.
DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; GLP/PIB, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Omibitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin. Cells have been left blank for the unassessed interactions with RBV.

For personal use only Not for distribution For personal use only Not for distribution For personal use only Not for distribution

Key to symbols

Key symbols
● These drugs should not be coadministered
■ Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲ Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆ No clinically significant interaction expected

Notes

- Notes**

 - Further information is available at www.hep-druginteractions.org
 - Predicted interactions are based on known metabolic pathways. Interaction studies performed with boceprevir and telaprevir have shown some inconsistencies which suggest unknown mechanisms may contribute to drug-drug interactions and therefore predictions may not always reflect the clinical situation.
 - Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
 - Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool
macclesy Research Lab, 1st Floor BL1

Pharmacology Research Labs, 1st Floor Block H,
70 Pembroke Place, LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or

HCV Directly Acting Antivirals & RBV

Charts revised July 2018. Full information available at www.hep-druginteractions.org

Page 3 of 5

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Caution Note: If a drug is not listed it cannot automatically be included in your regimen. DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; GLP/PIB, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Omibitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin. Cells have been left blank for the unassessed interactions with RBV.

For personal use only. Not for distribution. For personal use only. Not for distribution.

Key to symbols

- These drugs should not be coadministered
- Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
- ▲ Potential interaction likely to be of weak intensity.
Additional action/monitoring or dosage adjustment is unlikely to be required
- ◆ No clinically significant interaction expected

Notes

- Notes**

 - Further information is available at www.hep-druginteractions.org
 - Predicted interactions are based on known metabolic pathways. Interaction studies performed with boceprevir and telaprevir have shown some inconsistencies which suggest unknown mechanisms may contribute to drug-drug interactions and therefore predictions may not always reflect the clinical situation.
 - Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
 - Where advice differs between countries, the charts reflect the more cautious option

© Liverpool Drug Interactions Group,
University of Liverpool

University of Liverpool
Pharmacology Research Labs, 1st Floor Block H,
70 Pembroke Place, LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or

HCV Directly Acting Antivirals & RBV

Charts revised July 2018. Full information available at www.hep-druginteractions.org

Page 4 of 5

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Caution Note: If a drug is not listed it cannot automatically be assumed it is safe to co-administer. DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; GLP/PIB, Glicaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Omibitasvir/Pariaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin. Cells have been left blank for the unassessed interactions with RBV.

Key to symbols

- These drugs should not be coadministered
- Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
- ▲ Potential interaction likely to be of weak intensity.
Additional action/monitoring or dosage adjustment is unlikely to be required
- ◆ No clinically significant interaction expected

Notes

- Notes**

 - Further information is available at www.hep-druginteractions.org
 - Predicted interactions are based on known metabolic pathways. Interaction studies performed with boceprevir and telaprevir have shown some inconsistencies which suggest unknown mechanisms may contribute to drug-drug interactions and therefore predictions may not always reflect the clinical situation.
 - Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
 - Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool
molecular Research Lab, 1st Floor BL1

Pharmacology Research Labs, 1st Floor Block H,
70 Pembroke Place, LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or

HCV Directly Acting Antivirals & RBV

Charts revised July 2018. Full information available at www.hep-druginteractions.org

Page 5 of 5

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; GLP/PIB, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Omibitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin. Cells have been left blank for the unassessed interactions with RBV.

	DCV	EBR/ GZR	GLP/ PIB	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	SMV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RV
Illicit/Recreational											
Amphetamine	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Cannabis	♦	♦	♦	♦	▲	▲	♦	♦	♦	♦	♦
Cocaine	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Ecstasy (MDMA)	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
GHB (Gamma-hydroxybutyrate)	♦	■	■	♦	■	■	♦	♦	♦	♦	♦
LSD (Lysergic acid diethylamide)	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Mephedrone	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Methamphetamine	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Phencyclidine (PCP)	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Immunosuppressants											
Azathioprine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	■
Basiliximab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Brodalumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ciclosporin	♦	●	■	♦	■	■	●	♦	♦	●	♦
Eculizumab	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Etanercept	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fingolimod	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Lenalidomide	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Mycophenolate	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Pirfenidone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Sirolimus	♦	■	■	♦	●	●	♦	♦	♦	■	♦
Tacrolimus	♦	■	■	♦	●	●	■	♦	♦	■	♦
Lipid Lowering Agents											
Atorvastatin	■	■	●	■	●	●	■	♦	■	●	♦
Bezafibrate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Ezetimibe	♦	■	■	■	■	■	♦	♦	♦	■	♦
Fenofibrate	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fish oils	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Fluvastatin	■	■	■	■	■	■	■	♦	♦	●	♦
Gemfibrozil	♦	■	■	♦	♦	♦	♦	♦	♦	♦	♦
Lovastatin	■	■	●	■	●	●	●	♦	♦	●	♦
Pitavastatin	■	■	♦	■	■	■	■	♦	♦	●	♦
Pravastatin	■	■	♦	■	■	■	■	♦	♦	■	■
Rosuvastatin	■	■	■	●	■	■	■	♦	♦	●	●
Simvastatin	■	■	●	■	●	●	■	■	■	■	●
Oxytocics											
Ergometrine (ergonovine)	♦	■	■	■	●	●	●	●	♦	♦	♦
Mifepristone	▲	♦	♦	♦	♦	■	■	■	♦	♦	♦
Misoprostol	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Parkinsonism Agents											
Benztropine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Carbidopa	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Orphenadrine	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Pramipexole	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Rasagiline	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Ropinirole	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Steroids											
Bclometasone	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Betamethasone	♦	♦	♦	♦	■	■	■	■	♦	♦	♦
Budesonide	♦	♦	♦	♦	♦	●	●	●	♦	♦	♦
Ciclesonide	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Clobetasol (topical)	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Clobetasone (topical)	♦	♦	♦	♦	■	■	♦	♦	♦	♦	♦
Dexamethasone	●	■	■	■	■	■	■	●	♦	♦	■
Fludrocortisone	♦	♦	♦	♦	■	■	■	■	♦	♦	♦
Flunisolide	♦	♦	♦	♦	■	■	■	■	♦	♦	♦
Fluticasone	♦	♦	♦	♦	■	●	●	♦	♦	♦	♦
Hydrocortisone (topical)	♦	♦	♦	♦	■	■	■	♦	♦	♦	♦
Methylprednisolone	♦	♦	♦	♦	■	■	■	■	♦	♦	♦
Mometasone	♦	♦	♦	♦	●	●	●	♦	♦	♦	♦
Prednicarbate	♦	♦	♦	♦	■	■	■	♦	♦	♦	♦
Prednisone	♦	♦	♦	♦	■	■	■	♦	♦	♦	♦
Triamcinolone	♦	♦	♦	♦	●	●	●	■	♦	♦	♦
Urological Agents											
Alfuzosin	♦	♦	♦	♦	●	●	●	♦	♦	♦	♦
Desmopressin	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Dutasteride	♦	♦	♦	♦	■	■	■	♦	♦	♦	♦
Finasteride	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦	♦
Tamsulosin	♦	♦	♦	♦	■	■	■	■	♦	♦	♦
Tolterodine	♦	♦	♦	♦	■	■	■	■	♦	♦	♦

For personal use only Not for distribution For personal use only Not for distribution

Key to symbols

- These drugs should not be coadministered
- Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
- ▲ Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
- ◆ No clinically significant interaction expected

Notes

- Notes**

 - Further information is available at www.hep-druginteractions.org
 - Predicted interactions are based on known metabolic pathways. Interaction studies performed with boceprevir and telaprevir have shown some inconsistencies which suggest unknown mechanisms may contribute to drug-drug interactions and therefore predictions may not always reflect the clinical situation.
 - Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
 - Where advice differs between countries, the charts reflect the more cautious option

© Liverpool Drug Interactions Group,
University of Liverpool

Pharmacology Research Labs, 1st Floor Block H,
70 Pembroke Place, LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or